The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to discover new ways to improve and extend people’s lives. Our ambition at ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Learn about the launch of our new state-of-the-art space, built to accelerate innovation from the inside out and provide new solutions for employees, partners and ultimately, our patients. On a crisp ...

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to ...

The world has entered a new era of cancer care – and as scientific advances have dramatically improved outcomes, patients are more informed and empowered than ever to be their own treatment advocates.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

For the estimated 2.8 million people 1 living with multiple sclerosis (MS) worldwide, diagnosis is life-altering and can be overwhelming. The symptoms, including loss of vision, movement and sensation ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD 1. Read on to learn more about patient populations at risk. May 19, 2025 Elevated lipoprotein(a), also ...

Syftet med studien är att utvärdera effekt och säkerhet av remibrutinib (LOU064) när det ges till patienter med skovvis förlöpande multipel skleros. Studiens huvudsyfte är att ta reda på om patienter ...